echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Research and development daily Sanofi "Du Puliu monoanti" new adaptive disease was approved clinically

    Research and development daily Sanofi "Du Puliu monoanti" new adaptive disease was approved clinically

    • Last Update: 2021-01-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    2020.12.29 Research and Development NEWS: Phase 3 clinical success in the treatment of central neuropathological pain after spinal cord injury; AstraZeneone/Merca East Targeted Anti-Cancer Drug obtained 3 approvals in Japan; and Huang Pharmaceuticals submitted a listing application to the FDA for Sofantini; Novartis announced that a new drug for allergic conjunctivitis has been officially approved in China... We focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information reference.
    (click on the title, read the original) "Drug Research and Development" the first three total treatment of spinal cord injury after the central nervous pathological pain phase 3 clinical success! Japanese pharmaceutical company No. 13 recently announced that the evaluation of Tarlig's treatment of spinal cord injury (SCI) after the central nervous pathological pain (CNP) phase 3 study reached the main end.
    the study was conducted in 274 patients with post-spinal cord injury in Asia (Japan, South Korea, Taiwan, China) with central neuropathic pain, using a double-blind approach to assess the efficacy and safety of mirogabalin and placebo.
    (Bio Valley) (Drug Approval) AstraZeneatic/Merca East Targeted Anti-Cancer Drug received 3 approvals in Japan Recently, AstraZeneza and Merca announced that the targeted anti-cancer drug Lynparza has been approved in Japan to treat three advanced cancers: ovarian cancer, prostate cancer, pancreatic cancer.
    Specific adaptive disorders are: combined beva monoantigen, used to treat adult patients with ovarian cancer who are positive for ovarian defects after receiving first-line chemotherapy, for treating patients with despotic resistance prostate cancer with far-stage metastasis and BRCA gene mutations, and for treating non-excisive BRCAm pancreatic cancer patients who have no progress after receiving first-line chemotherapy.
    (Bio Valley) and Yellow Pharma submitted Sovantinie's listing application to the FDA on the 28th, and Huang Pharma announced that it has begun rolling the submission to the FDA of the first part of Sovantini's new drug listing application (NDA) for the treatment of pancreatic and non-pancreatic neuroendocrine tumors (NDA), and plans to complete the new drug listing application in the first half of 2021, which will be the first U.S. drug listing application.
    (Medical Rubik's Cube) Korsuva Injection Seeking Priority Review Cara Therapeutics announced today that it has submitted a new drug application for Korsuva injections to the FDA to treat severe itching in hemodialysis patients.
    Korsuva is a small molecular inhibitor that selectively targets exosome opioids.
    it has been recognized as a breakthrough therapy awarded by the FDA.
    (Pharmaceutical Mingkangde) Novartis announced the official approval of a new drug for allergic conjunctivitis in China on the 29th, Novartis announced that Pataday was approved by the China Drug Administration for the treatment of allergic conjunctivitis-related itching eyes.
    , according to a press release, Pataday is an upgraded version of olotta hydrochloride.
    it increased the concentration of olotatin hydrochloric acid to 0.2%, not only to continue to maintain the dual-effect anti-sensitivity mechanism, but also to reduce the frequency of use, for China's allergic conjunctivitis patients to bring more convenient treatment options.
    (Pharmaceutical Mingkangde) Lilly Abersili tablets to China again submitted the new adaptive drug listing application CDE website latest publicity, Lilly in China submitted three CDK 4/6 inhibitor Abesili tablets of the new adaptive drug listing application, and was accepted on December 28.
    it is worth noting that in China, the first adaptive application for female breast cancer patients is in the approval stage.
    the acceptance of the new adaptation application means that the Abesili tablet is expected to benefit more Chinese breast cancer patients.
    (Pharmaceutical Mingkangde) Johnson and Johnson amivatamab EU application listed Johnson and Johnson's Janssen Pharmaceuticals recently announced that it has submitted a marketing authorization application to the EMA, seeking approval for amivantamab, for the treatment of patients with metastasis non-small cell lung cancer who are progressing after the failure of platinum-containing chemotherapy, exosome No. 20 of the dermis growth factor gene.
    month, Janssen Pharmaceuticals also filed a biopharmaceutical license application for the amivantamab.
    (Bio Valley) Shishi Shiguibao Zeposia in the European Union formally applied for the new adaptive Shimi shiguibo recently announced that the EMA has accepted Zeposia's marketing authorization application for the treatment of moderate to severe ulcerative colitis adult patients.
    , the EMA has started a centralized review process.
    if approved, Zeposia will be the first oral arginol-1-phosphate-subject regulator to treat ulcerative colitis.
    (Bio Valley) Sanofi "Du Puliu mono-anti" new adaptive disease was approved clinically 29, Sanofi according to class 2.2 submitted a clinical application for dupley mono-anti-injection new adaptive clinical application by CDE default license, intended to develop for the treatment of chronic sinusitis not accompanied by nasal psalms (CRSsNP).
    biological products according to category 2.2 declaration means: increase the number of new adaptations and/or changes in drug use who have not been approved at home or a foreign country.
    (Medical Rubik's Cube) 3rd! Zhengda Tianqing "Malay acid afatini tablets" approved for listing Is Day Qing according to the new 4 categories of submitted Malay acid afatini tablet generic drug market applications approved by the State Drug Administration, becoming the third domestic product approved for listing enterprises, approved as follows through a consistent evaluation.
    (Pharmaceutical Rubik's Cube) is the first fda-approved constipation drug Ruby protone Nanjing Zhengda Qing to copy the 3 categories of submitted Ruby protruding ketone capsule listing application to obtain CDE contractor acceptance, the product is currently in a blank state in the domestic market, Nanjing Zhengda Tianqing first reported production.
    is the first FDA-approved chemical to treat constipation, with global sales of 28.1 billion yen in 2019.
    the first review in the World Wide Office (Minanet)! Stone drug Euro-Italian "Dasatini tablets" will soon be approved for the market of stone-drug European-Italian according to category 4 submitted Dasatini tablets listing applications in the "in-approval" state, is expected to be approved in the near future, becoming the first variety through the consistent evaluation of manufacturers.
    (Medical Rubik's Cube)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.